Clinical Scorecard: Phase 1b LOTUS Trial Targets IL-6R for DME

At a Glance

Key Highlights

• EB-105 is a novel pentavalent trispecific fusion antibody addressing VEGF pathways plus IL-6R inflammatory pathway.
• Phase 1 trial showed safety, tolerability, and no serious adverse events in 13 patients with DME over 3 months.
• Single injection led to mean 7-letter BCVA gain and ~100 μm CST reduction, with some patients improving up to 21 letters.

Guideline-Based Recommendations

Diagnosis

• Confirm DME diagnosis with central subfield thickness (CST) ≥325 μm and best-corrected visual acuity (BCVA) between 20/40 and 23/20.
• Exclude proliferative diabetic retinopathy in patient selection.

Management

• Consider novel agents targeting multiple pathways including VEGF-A, VEGF-B, PIGF, ANG-2, and IL-6R for improved efficacy.
• EB-105 shows promise as a single-dose treatment with potential for prolonged effect; further studies needed.

Monitoring & Follow-up

• Monitor BCVA and CST to assess treatment response.
• Observe for adverse events including ocular inflammation and systemic exposure.
• Evaluate need for rescue therapy, especially in lower dose groups.

Risks

• No dose-limiting toxicities or drug-related adverse events reported in phase 1 trial.
• Ongoing monitoring for ocular inflammation and systemic pharmacokinetics recommended.

Patient & Prescribing Data

Adults with diabetic macular edema, including those previously treated with anti-VEGF agents.

EB-105 was safe and well tolerated with clinically relevant improvements in vision and retinal thickness after a single injection; dose response observed.

Clinical Best Practices

• Use inclusion criteria consistent with prior DME trials for patient selection.
• Consider multi-targeted therapies addressing inflammatory and angiogenic pathways for complex DME cases.
• Plan for longer-term and multiple-dose studies to establish durability and optimal dosing.

References

• Phase 1b LOTUS Trial Data Presentation
• Faricimab Clinical Trials